Expression of costimulatory molecule B7-H3 and its prognostic implications in human acute leukemia

Hematology

Volumn 20, Issue 4, 2015, Pages 187-195

  Hu, Yixin ^a,b   Lv, Xin ^a,c   Wu, Yujie ^a   Xu, Ji ^a   Wang, Lingling ^a   Chen, Weifeng ^a   Zhang, Wei ^a   Li, Jianyong ^a   Zhang, Sujiang ^a   Qiu, Hongxia ^a  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^b CHILDREN S HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^c Yishui Central Hospital of Linyi   (China)

Author keywords

Acute lymphocytic leukemia; Acute myeloid leukemia; B7 H3; Costimulatory molecule; Prognosis

Indexed keywords

B7H3; CD34 ANTIGEN; MESSENGER RNA; PROTEIN; UNCLASSIFIED DRUG; B7 ANTIGEN; CD276 PROTEIN, HUMAN;

ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ADULT; AGED; ARTICLE; CHILD; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNOPHENOTYPING; KARYOTYPE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; SHORT TERM SURVIVAL; UNIVARIATE ANALYSIS; ADOLESCENT; GENE EXPRESSION REGULATION; GENETICS; INFANT; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; PRESCHOOL CHILD; PROGNOSIS; SURVIVAL; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; B7 ANTIGENS; CHILD; CHILD, PRESCHOOL; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; INFANT; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; PROGNOSIS; RNA, MESSENGER; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 84928563696     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1179/1607845414Y.0000000186     Document Type: Article

References (34)

1. Rubnitz JE, Gibson B, Smith FO. Acute myeloid leukemia. Hematol Oncol Clin North Am. 2010;24:35–63.
2. Estey EH. Acute myeloid leukemia: 2012 update on diagnosis, risk stratification, and management. Am J Hematol. 2012;87: 89–99.
3. Grimwade D, Hills RK. Independent prognostic factors for AML outcome. Hematol Am Soc Hematol Educ Program 2009;1:385–95.
4. Dalal BI, Mansoor S, Manna M, Pi S, Sauro GD, Hogge DE. Detection of CD34, TdT, CD56, CD2, CD4, and CD14 by flow cytometry is associated with NPM1 and FLT3 mutation status in cytogenetically normal acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2012;12:274–9.
5. Iwamoto S, Deguchi T, Ohta H, Kiyokawa N, Tsurusawa M, Yamada T, et al. Flow cytometric analysis of de novo acute lymphoblastic leukemia in childhood: report from the Japanese Pediatric Leukemia/Lymphoma Study Group. Int J Hematol. 2011;94:185–92.
6. Cheuk AT, Wells JW, Chan L, Westwood NB, Berger SA, Yagita H, et al. Anti-tumor immunity in a model of acute myeloid leukemia. Leuk Lymphoma 2009;50:447–54.
7. Abbas AK. The control of T cell activation vs. tolerance. Autoimmun Rev. 2003;2:115–8.
8. Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family revisited. Annu Rev Immunol. 2005;23:515–48.
9. Chapoval AI, Ni J, Lau JS, Wilcox RA, Flies DB, Liu D, et al. B7-H3: a costimulatory molecule for T cell activation and IFN-γ production. Nat Immunol. 2001;2:269–74.
10. Sun Y, Wang Y, Zhao J, Gu M, Giscombe R, Lefvert AK, et al. B7-H3 and B7-H4 expression in non-small-cell lung cancer. Lung Cancer 2006;53:143–51.
11. Loos M, Hedderich DM, Ottenhausen M, Giese NA, Laschinger M, Esposito I, et al. Expression of the costimulatory molecule B7-H3 is associated with prolonged survival in human pancreatic cancer. BMC Cancer 2009;9:463.
12. Wu CP, Jiang JT, Tan M, Zhu YB, Ji M, Xu KF, et al. Relationship between costimulatory molecule B7-H3 expression and gastric carcinoma histology and prognosis. World J Gastroenterol. 2006;12:457–9.
13. Zang X, Sullivan PS, Soslow RA, Waitz R, Reuter VE, Wilton A, et al. Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomas. Mod Pathol. 2010;23: 1104–12.
14. Boorjian SA, Sheinin Y, Crispen PL, Lohse CM, Leibovich BC, Kwon ED. T-cell co-regulatory molecule expression in renal angiomyolipoma and pulmonary lymphangioleiomyomatosis. Urology 2009;74:1359–64.
15. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008 revision of the WHO classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009;114:937–51.
16. Gattei V, Degan M, Gloghini A, De Iuliis A, Improta S, Rossi FM, et al. CD30 ligand is frequently expressed in human hematopoietic malignancies of myeloid and lymphoid origin. Blood 1997;89:2048–59.
17. Loos M, Hedderich DM, Friess H, Kleeff J. B7-H3 and its role in antitumor immunity. Clin Dev Immunol. 2010;2010:1–7.
18. Gotsman I, Sharpe AH, Lichtman AH. T-cell costimulation and coinhibition in atherosclerosis. Circ Res. 2008;103:1220–31.
19. Sharpe AH, Freeman GJ. The B7-CD28 superfamily. Nat Rev Immunol. 2002;2:116–26.
20. Collins M, Ling V, Carreno BM. The B7 family of immune-regulatory ligands. Genome Biol. 2005;6:223.
21. Zang X, Loke P, Kim J, Murphy K, Waitz R, Allison JP. B7x: a widely expressed B7 family member that inhibits T cell activation. Proc Natl Acad Sci USA 2003;100:10388–92.
22. Liu X, Gao JX, Wen J, Yin L, Li O, Zuo T, et al. B7DC/PDL2 promotes tumor immunity by a PD-1-independent mechanism. J Exp Med. 2003;197:1721–30.
23. Loos M, Giese NA, Kleeff J, Giese T, Gaida MM, Bergmann F, et al. Clinical significance and regulation of the costimulatory molecule B7-H1 in pancreatic cancer. Cancer Lett. 2008;268: 98–109.
24. Ghebeh H, Mohammed S, Al-Omair A, Qattan A, Lehe C, Al- Qudaihi G, et al. The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. Neoplasia 2006;8:190–8.
25. Crispen PL, Sheinin Y, Roth TJ, Lohse CM, Kuntz SM, Frigola X, et al. Tumor cell and tumor vasculature expression of B7-H3 predict survival in clear cell renal cell carcinoma. Clin Cancer Res. 2008;14:5150–7.
26. Sun J, Chen LJ, Zhang GB, Jiang JT, Zhu M, Tan Y, et al. Clinical significance and regulation of the costimulatory molecule B7-H3 in human colorectal carcinoma. Cancer Immunol Immunother. 2010;59:1163–71.
27. Boorjian SA, Sheinin Y, Crispen PL, Farmer SA, Lohse CM, Kuntz SM, et al. T-cell coregulatory molecule expression in urothelial cell carcinoma: clinicopathologic correlations and association with survival. Clin Cancer Res. 2008;14:4800–8.
28. Roth TJ, Sheinin Y, Lohse CM, Kuntz SM, Frigola X, Inman BA, et al. B7-H3 ligand expression by prostate cancer: a novel marker of prognosis and potential target for therapy. Cancer Res. 2007;67:7893–900.
29. Zang X, Thompson RH, Al-Ahmadie HA, Serio AM, Reuter VE, Eastham JA, et al. B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome. Proc Natl Acad Sci. 2007;104:19458–63.
30. Holden JT, Geller RB, Farhi DC, Holland HK, Stempora LL, Phillips CN, et al. Characterization of Thy-1(CDw90) expression in CD34+ acute leukemia. Blood 1995;86:60–5.
31. Kozii R, Wilson J, Persichetti J, Phelps V, Ball SE, Ball ED. Thy-1 expression on blast cells from adult patients with acute myeloid leukemia. Leuk Res. 1997;21:381–5.
32. Kyoda K, Nakamura S, Hattori N, Takeshima M, Nakamura K, Kaya H, et al. Lack of prognostic significance of CD34 expression in adult AML when FAB M0 and M3 are excluded. Am J Hematol. 1998;57:265–6.
33. Fruchart C, Lenormand B, Bastard C, Boulet D, Lesesve JF, Callat MP, et al. Correlation between CD34 expression and chromosomal abnormalities but not clinical outcome in acute myeloid leukemia. Am J Hematol. 1996;53:175–80.
34. Fagioli F, Cuneo A, Carli MG, Bardi A, Piva N, Previati R, et al. Chromosome aberrations in CD34-positive acute myeloid leukemia: correlation with clinicopathologic features. Cancer Genet Cytogenet. 1993;71:119–24.